Phase II study of autologous stem cell transplant using busulfanmelphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 51, Issue 4, 2010, Pages 641-649

  Grigg, Andrew P ^a   Stone, Janey ^b   Milner, Alvin D ^b   Schwarer, Anthony P ^c   Wolf, Max ^a   Prince, H Miles ^a   Seymour, John ^a   Gill, Devinder ^d   Ellis, David ^e   Bashford, John ^f  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c ALFRED HOSPITAL   (Australia)

^d PRINCESS ALEXANDRA HOSPITAL   (Australia)

^e FLINDERS MEDICAL CENTRE   (Australia)

^f WESLEY HOSPITAL   (Australia)

Author keywords

Autograft; Interferon; Low grade NHL

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; MITOXANTRONE; PREDNISONE; RECOMBINANT ALPHA2B INTERFERON; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; HUMAN TISSUE; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; SALVAGE THERAPY; STEM CELL MOBILIZATION; TREATMENT OUTCOME;

ADULT; BUSULFAN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERONS; LYMPHOMA, NON-HODGKIN; MALE; MELPHALAN; MIDDLE AGED; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 77953201114     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428191003611428     Document Type: Article

References (43)

1. Smalley R, Andersen J, Hawkins M, et al. Interferon alfa combined with cytotoxic chemotherapy for patients with non- Hodgkin's lymphoma. N Engl J Med 1992;327:1336-1341.
2. Solal-Celigny P, Lepage E, Brousse N, et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma: Grupe d'Elude des Lymphomes de l'Adulte. N Engl J Med 1993;329:1608-1614.
3. Rohatiner A, Johnson P, Price C, et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 1994;12:1177-1184. (Pubitemid 24173931)
4. Bastion Y, Brice P, Haioun C, et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 1995;86: 3257-3262.
5. Weisdorf D, Anderson J, Glick J, Oken M. Survival after relapse of low-grade non-Hodgkin's lymphoma: implications for marrow transplantation. J Clin Oncol 1992;10:942-947.
6. Montoto S, Lopez-Guillermo A, Ferrer A, et al. Survival after progression in patients with follicular lymphoma: analysis of prognostic factors. Ann Oncol 2002;13:523-530.
7. Unterhalt M, Hermann P, Koch P, et al. Prognostic determinants for long term outcome of low grade follicular lymphomas after cytoreductive chemotherapy and interferon alpha maintenance. Results of the German Low Grade Lymphoma Study Group (GLSG). Blood 1997;90(Suppl. 1):392 (Abstract 1743).
8. Seymour J, Robertson L, O'Brien S, Lerner S, Keating M. Survival of young patients with chronic lymphocytic leukemia failing fludarabine therapy: a basis for the use of myeloablative therapies. Leuk Lymphoma 1995;18:493-496.
9. Grigg AP, Clarke K, Szer J. Prolonged disease-free survival after autografting for chemosensitive non-bulky low grade non-Hodgkin's lymphoma. Leuk Lymphoma 2000;39:283-290.
10. Darrington D, Vose J, Anderson J, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 1994;12:2527-2534.
11. Schenkein D, Dixon P, Desforges J, et al. Phase I/II study of cyclophosphamide, carboplatin, and etoposide and autologous hematopoietic stem-cell transplantation with posttransplant interferon alfa-2b for patients with lymphoma and Hodgkin's disease. J Clin Oncol 1994;12:2423-2431.
12. Cheson B, Horning S, Coiffier B, et al. Report on an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244-1253.
13. Schemper M, Smith T. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996;17:343-346.
14. Keeney G, Gooley T, Pham R, et al. The pretransplant follicular lymphoma international prognostic index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantation. Leuk Lymphoma 2007;48:1961-1967.
15. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2006;106:1417-1423.
16. Hiddemann W, Kneba M, Dreyling M, et al. Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low Grade Lymphoma Study Group. Blood 2006;106:3725-3732.
17. Herold M, Hass A, Srock S, et al. Rituximab added to firstline mitoxantrone, chlorambucil and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007;25:1966-1992.
18. van Oers M, Klasa R, Marcus R, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non- Hodgkin's lymphoma in patients both with and without rituximab during induction: results of a prospective randomised phase 3 intergroup trial. Blood 2006;108:3295-3301.
19. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomised study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108:4003-4008.
20. Ladetto M, De Marco F, Benedetti F, et al., for Guppo Italiano Trapianto di Midollo Osseo (GITMO), Intergruppo Italiano Linfomi (IIL0). Prospective, multicenter randomized GITMO/IIL tiral comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008;111:4004-4013.
21. McLaughlin P, Hagemeister FB, Romaguera JE, et al. Fludarabine, mitoxantrone and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 1996;14:1262-1268.
22. Hertzberg M, Grigg A, Gottlieb D, et al. Reduced intensity allogeneic haemopoietic stem cell transplantation induces durable responses in patients with chronic B lymphoproliferative disorders. Bone Marrow Transplant 2006;37:923-928.
23. Apostolidis J, Gupta R, Grenzelias D, et al. High dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol 2000;18:527-536.
24. Brice P, Simon D, Bouabdallah R, et al. High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. Ann Oncol 2000;11:1585-1590.
25. Cao T, Horning S, Negrin R, et al. High dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience. Biol Blood Marrow Transplant 2001;7:294-301.
26. Freedman A, Neuberg D, Mauch P, et al. Long-term followup of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999;94:3325-3333. (Pubitemid 29536125)
27. Laudi N, Arora M, Burns LJ, et al. Long-term follow-up after autologous hematopoietic stem cell transplantation for lowgrade non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005;11:129-135.
28. Schouten H, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003;21:3918-3927.
29. Vose J, Bierman P, Loberiza F, et al. Long-term outcomes of autologous stem cell transplantation for follicular non- Hodgkin lymphoma: effect of histological grade and follicular international prognostic index. Biol Blood Marrow Transplant 2008;14:36-42.
30. Rohatiner A, Nadler L, Davies A, et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long term follow up. J Clin Oncol 2007;15:2554-2559.
31. Bolwell B, Kalaycio M, Sobecks R, et al. Autologous hematopoietic cell transplantation non-Hodgkin's lymphoma: 100 month follow up. Bone Marrow Transplant 2002;29:673-679.
32. Montoto S, Canals C, Rohatiner A, et al. Long-term follow up of high dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EMBT registry study. Leukemia 2007;21: 2324-2331.
33. Pham R, Gooley T, Keeney G, et al. The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma. Bone Marrow Transplant 2007;40:1039-1044.
34. Lenz G, Dreyling M, Schiegnitz E, et al. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. J Clin Oncol 2004;22:4926-4933. (Pubitemid 46638617)
35. Brown J, Yekes H, Friedberg W, et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2005;23:2208-2214.
36. Hiddemann W, Griesinger F, Unterhalt M. Interferon alfa for the treatment of follicular lymphomas. Cancer J Sci Am 1998;4:S13-S18.
37. Rohatiner A, Gregroy W, Peterson B, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005;23:2215-2223.
38. Bosly A, Lepage E, Grigg A, et al. Interferon a2b does not prolong response after intensive therapy and autologous stem cell transplantation for relapsing lymphoma. An international randomized study of 221 patients. Blood 2001;98(Suppl. 1):862 (Abstract 3579).
39. Corradini P, Ladetto M, Zallio F, et al. Long term follow up of indolent lymphoma patients treated with high dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol 2004;22:1460-1468.
40. Kimby E, Jurlander J, Geisler C, et al. Long term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group. Leuk Lymphoma 2008;49:102-112.
41. Salles G, Mounier N, du Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008;112:4824-4831.
42. Sebban C, Brice P, Delarue R, et al. Impact of rituximab and/ or high dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 2008;26:3614-3620.
43. Kang T, Rybicki L, Bolwell B, et al. Effect of prior rituximab on high dose therapy and autologous stem cell transplantation in follicular lymphoma. Bone Marrow Transplant 2007;40: 973-978.